Evidence map›Paper›PMID 39331162›Full record

Observational studyActa neurochirurgica2024

Anticoagulation strategies in patients with coexisting traumatic intracranial hematomas and cerebral venous sinus thrombosis: an observational cohort study.

Julia Antonsson, Charles Tatter, Anna Ågren, Peter Alpkvist, Eric Peter Thelin, Alexander Fletcher-Sandersjöö

Abstract readObservational Study
In one paragraph

Observational study in Acta neurochirurgica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Julia AntonssonDepartment of Clinical Neuroscience, Karolinska Institutet, Bioclinicum J5:20, 171 64-Solna, Stockholm, Sweden.
Charles TatterDepartment of Clinical Neuroscience, Karolinska Institutet, Bioclinicum J5:20, 171 64-Solna, Stockholm, Sweden.
Anna ÅgrenCoagulation Unit, Hematology Centre, Karolinska University Hospital, Stockholm, Sweden.
Peter AlpkvistDepartment of Clinical Neuroscience, Karolinska Institutet, Bioclinicum J5:20, 171 64-Solna, Stockholm, Sweden.
Eric Peter ThelinDepartment of Clinical Neuroscience, Karolinska Institutet, Bioclinicum J5:20, 171 64-Solna, Stockholm, Sweden.
Alexander Fletcher-SandersjööDepartment of Clinical Neuroscience, Karolinska Institutet, Bioclinicum J5:20, 171 64-Solna, Stockholm, Sweden. alexander.fletcher-sandersjoo@ki.se.

Funding

Karolinska Institutet Research Grants 2022-01576Region Stockholm ALF FoUI-962566Region Stockholm Clinical Research Appointment FoUI-981490The Swedish Brain Foundation FO2023-0124The Swedish Society of Medicine SLS-985504
6 · The paper itself

Abstract

purposePost-traumatic cerebral venous sinus thrombosis (ptCVT) is a rare but serious complication of traumatic brain injury (TBI). Managing ptCVT is challenging due to the concurrent risk of traumatic intracranial hematoma (ICH) expansion. Limited data exists on the safety and efficacy of anticoagulation therapy (ACT) in these cases.

methodsThis single-center observational cohort study included adult TBI patients with concurrent ICH and ptCVT. Low-molecular-weight heparin (LMWH) or heparin infusion was used to treat all ptCVTs based on institutional protocols. The outcomes of interest were hemorrhagic and thrombotic complications.

resultsOut of 1,039 TBI-patients admitted between 2006 and 2020, 32 met the inclusion criteria. The median time from injury to ptCVT diagnosis was 24 h. ACT was initiated at a median of 9 h after ptCVT diagnosis. Patients were administered either heparin infusion (n = 8) or LMWH at dosages ranging from 28 to 72% of the therapeutic level (n = 24). There were no hemorrhagic complications, even in patients receiving LMWH at ≥ 50% of the therapeutic dose. Thrombotic complications occurred in 3 patients (9.4%) - two cases of thrombus progression and one venous infarct. The patients who developed thrombotic complications differed from those who did not by having a 17-h delay in ACT initiation after diagnosis or by receiving an initial LMWH dose at 28% of the therapeutic level.

conclusionLMWH at approximately 50% of the therapeutic level was effective for managing ptCVT associated with TBI in our retrospective dataset, with no risk of hematoma expansion. Prospective trials are warranted to confirm these results.

Indexed as

AnticoagulantsHeparin, Low-Molecular-WeightSinus Thrombosis, IntracranialAdultAgedBrain Injuries, TraumaticCohort StudiesFemaleHeparinHumansIntracranial Hemorrhage, TraumaticMaleMiddle AgedRetrospective StudiesAnticoagulantsHeparinHeparin, Low-Molecular-WeightAnticoagulationCerebral venous sinus thrombosisDural sinus thrombosisIntracranial hematomaTraumatic brain injury

Identifiers

PMID39331162
PMCPMC11436407

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.